Seaport Therapeutics, Inc. director Denice Torres purchased 5,000 common shares on November 3, 2026, at $19.8650 per share; her reported direct holdings after the purchase were 5,000 shares. No Rule 10b5-1 plan is reported for the purchase. A separate holding entry lists 13,406 shares held by the Denice M. Torres Revocable Trust as of November 3, 2026. Torres disclaims beneficial ownership of those shares for Section 16 purposes, except to the extent of her pecuniary interest, if any.
Seaport Therapeutics, Inc. reported a third-quarter net loss of $26.4 million, versus $22.5 million a year earlier, and research and development expense of $23.9 million versus $20.5 million. For the first nine months of 2026, net loss was $114.4 million versus $50.7 million in 2025; operating cash used was $69.0 million versus $51.3 million. Nine-month general and administrative expense included $39.1 million of non-cash stock-based compensation.
As of September 30, 2026, Seaport had $403.8 million in cash, cash equivalents and investments; management believes this will fund operations for at least twelve months from issuance of the statements. The company completed its IPO in May 2026, selling 14,446,658 shares at $18.00 each for $238.4 million in net proceeds. Its preferred stock converted into 36,272,475 common shares at the IPO closing.
Seaport has no product-sales revenue and remains focused on clinical development. The Phase 2b BUOY-1 trial of GlyphAllo is underway, with topline data expected in the first half of 2027. Seaport reported that evening GlyphAllo dosing did not impair next-morning driving performance versus placebo in a Phase 1 simulation. It dosed the first patient in a GlyphAgo Phase 2a trial in October 2026 and expects topline data in early 2028.
Seaport Therapeutics, Inc. reported third-quarter 2026 net loss of $26.394 million, compared with $22.544 million a year earlier. Research and development expenses were $23.891 million versus $20.453 million, and general and administrative expenses were $6.454 million versus $4.988 million. Cash, cash equivalents and investments totaled $403.799 million as of September 30, 2026; the company expects these resources to support current operating plans into 2029 and through three mid-to-late-stage data readouts.
A Phase 1 driving simulation trial found that evening GlyphAllo doses of 375 mg after multiple-day dosing on Day 5 and a single 250 mg dose on Day 2 did not impair next-morning driving performance compared with placebo; no serious adverse events were reported. BUOY-1, a Phase 2b GlyphAllo trial in major depressive disorder, is enrolling, with topline data expected in the first half of 2027. Seaport dosed the first patient in its GlyphAgo Phase 2a trial for generalized anxiety disorder and sleep disturbance, and expects to initiate a Phase 2/3 GAD trial in the first half of 2027. Topline data are expected in early 2028 from Phase 2a and by year-end 2028 from Phase 2/3.
PureTech Health plc, together with its affiliates PureTech Health LLC and PureTech LYT, Inc., reports beneficial ownership of 16,685,013 shares of Seaport Therapeutics, Inc. Voting Common Stock as of June 30, 2026. This represents 31.2% of the class, based on 53,530,550 shares outstanding as of July 27, 2026.
PureTech LYT, Inc. is the record holder of the shares, while PureTech Health LLC and PureTech Health plc indirectly control them through ownership of the subsidiary entities, with shared voting and dispositive power over all 16,685,013 shares.
Daphne Zohar reports beneficial ownership of Voting Common Stock of Seaport Therapeutics, Inc. as of June 30, 2026. She is deemed to beneficially own 5,225,497 shares of common stock, based on 53,530,550 shares outstanding, representing 9.1% of the class.
The position includes 1,194,001 shares held of record and 4,031,496 shares subject to stock options exercisable within 60 days of June 30, 2026. She has sole voting and sole dispositive power over all 5,225,497 shares, with no shared voting or dispositive power reported.
Seaport Therapeutics, Inc. reports that Steven M. Paul beneficially owns 3,516,718 shares of its Voting Common Stock as of June 30, 2026. This amount represents 6.3% of the 53,530,550 shares of Common Stock stated to be outstanding on that date.
The position consists of 863,031 shares held of record by Steven M. Paul and 2,653,687 shares underlying stock options that are exercisable within 60 days of June 30, 2026. He has sole voting and dispositive power over all 3,516,718 shares and no shared voting or dispositive power.
Seaport Therapeutics, a clinical-stage neuropsychiatry company using its proprietary Glyph platform, reported a net loss of $62.6 million for Q2 2026 and $88.0 million for the first half of 2026. Year-to-date operating expenses were $93.4 million, including $46.0 million in research and development and $47.3 million in general and administrative costs. G&A expenses reflect substantial non-cash stock-based compensation, including $37.6 million in general and administrative awards and $1.8 million in research and development.
Liquidity improved following the IPO. As of June 30, 2026, total assets were $441.7 million, including $427.3 million of cash, cash equivalents and U.S. Treasury investments, which management believes will fund operations for at least twelve months. During Q2 2026, the company completed its IPO, issuing 14,446,658 shares at $18.00 per share for approximately $238.4 million in net proceeds, and all preferred stock converted into common shares, resulting in 53,530,550 common shares outstanding.
Pipeline programs advanced. Lead candidate GlyphAllo is in the Phase 2b BUOY-1 trial in major depressive disorder, with topline data expected in the first half of 2027, and a Phase 1 driving simulation study reading out in the second half of 2026. GlyphAgo completed Phase 1 with favorable pharmacokinetics and safety, with Phase 2 trials in generalized anxiety disorder planned from late 2026.
Seaport Therapeutics reported second-quarter 2026 results and detailed progress across its neuropsychiatry pipeline. Enrollment in the Phase 2b BUOY-1 trial of GlyphAllo in major depressive disorder is on track, with topline data expected in the first half of 2027, and a Phase 1 driving-simulation trial is expected to read out in the second half of 2026.
The company reported positive Phase 1 proof-of-concept data for GlyphAgo in generalized anxiety disorder, including a 6.8-fold increase in bioavailability and 10-fold lower pharmacokinetic variability versus unmodified agomelatine, supporting planned Phase 2a and 2b trials starting in 2026 and 2027. Preclinical candidate Glyph2BLSD is expected to complete first-in-human-enabling studies by year-end 2027.
In May 2026 Seaport completed an upsized IPO raising $260.0 million in gross proceeds, ending June 30, 2026 with $427.3 million in cash, cash equivalents, and investments, which it expects to fund operations into 2029. Higher R&D and one-time, non-cash stock-based compensation drove a wider net loss of $62.6 million for the quarter, compared with $15.1 million a year earlier.
Seaport Therapeutics director–related trust bought additional stock. On behalf of the Robert Joseph Hombach Revocable Trust, an open-market purchase of 13,000 shares of Seaport Therapeutics common stock was made at a weighted average price of $18.136 per share, with individual trades ranging from $17.65 to $18.27.
After this transaction, the trust holds 13,000 shares indirectly attributed to director Robert J. Hombach. He disclaims beneficial ownership of these shares for Section 16 purposes except to the extent of any pecuniary interest.
Seaport Therapeutics, Inc. is a clinical‑stage biotech developing oral therapies for depression, anxiety and other neuropsychiatric disorders using its Glyph platform. For the quarter ended March 31, 2026, it reported a net loss of $25.4 million, wider than $13.1 million a year earlier, driven mainly by higher research and development spending.
R&D expenses nearly doubled to $21.4 million as the company advanced its lead candidate GlyphAllo into a Phase 2b BUOY‑1 trial in major depressive disorder and ran supporting studies, while GlyphAgo progressed through Phase 1 with favorable bioavailability and safety data. General and administrative expenses were $6.1 million, reflecting public‑company preparation and growth in corporate infrastructure.
Seaport ended the quarter with $52.9 million in cash and cash equivalents and $159.7 million in U.S. Treasury investments, totaling $212.6 million in cash and investments. Management states that, combined with approximately $238.7 million of net proceeds from its second‑quarter 2026 IPO, these resources are expected to fund operations into 2029 while the pipeline advances through multiple planned Phase 2 trials.